Back to top

Analyst Blog

Supernus Pharmaceuticals, Inc. (SUPN - Snapshot Report) recently announced the launch of its antiepileptic drug, Oxtellar XR, in the US. Oxtellar XR was approved by the US Food and Drug Administration (FDA) in Oct 2012. Supernus’ 75-person sales force has started promoting the product.

Oxtellar XR is a novel once-daily extended release formulation of oxcarbazepine. Oxtellar XR is an antiepileptic drug (AED) indicated for adjunctive therapy for the treatment of partial seizures in adults and in children 6 to 17 years of age.

In Nov 2012, Supernus received three years of marketing exclusivity from the FDA.

Supernus has another epilepsy product named Trokendi XR, which received tentative FDA approval in Jun 2012. Supernus is likely to launch this product in the third quarter of 2013 provided it gains final approval from the FDA.

Our Take

The launch of Oxtellar XR is a significant milestone for the company. Supernus’s main area of focus is the development of products for central nervous system (CNS) disorders. The company’s pipeline includes SPN-810 (completed phase IIb) for the treatment of impulsive aggression in attention deficit hyperactivity disorder (ADHD) patients and SPN-812 (completed phase IIa) for ADHD.

In Nov 2012, the company announced encouraging top-line results from a phase IIb study on SPN-810, across three doses. The company plans to advance the candidate into phase III trials and will meet the FDA to discuss the trial design and protocol for the same.

Currently approved AED drugs include Shire plc’s (SHPG - Analyst Report) Carbatrol and UCB (UCBJF)’s Keppra XR.

Supernus carries a Zacks Rank #3 (Hold). Right now, Pernix Therapeutics Holdings, Inc. carries a Zacks Rank #2 (Buy). 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%
STRATTEC SE… STRT 80.24 +3.00%